\-\ Texto\\:\\ \ \(0\)\
\-\ cbc\\:\\ normal\ \(0\)\
\-\ serum\\ chemistry\\ panel\\:\\ normal\ \(0\)\
\-\ ua\\:\\ blood\\ and\\ rbcs\\ noted\\,\\ otherwise\\ normal\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ back\\:\\ \\ no\\ cvat\ \(0\)\
\-\ lungs\\:\\ ctab\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ gu\\:\\ \\ normal\\ female\\ external\\ genitalia\ \(0\)\
\-\ abdominal\\ exam\\:\\ soft\\,\\ obvious\\ right\\ sided\\ mass\\,\\ relatively\\ non\\-tender\\.\\ \\ \\ \\ \\ \\ \\ \\ extremities\\:\\ \\ all\\ pulses\\ 2\\+\\ palpable\\,\\ equal\ \(0\)\
\-\ patient\\ underwent\\ right\\ radical\\ nephrectomy\\ and\\ exploration\\ of\\ left\\ kidney\\.\\ \\ uneventful\\ hospital\\ course\\.\\ \\ discharged\\ to\\ home\\ on\\ pod\\ \\#6\\ following\\ first\\ course\\ of\\ chemotherapy\\ by\\ pediatric\\ oncology\\ service\\.\ \(0\)\
\-\ ruq\\ ultrasound\\:\\ \\ a\\ large\\ mass\\ is\\ seen\\ in\\ the\\ right\\ upper\\ quadrant\\ in\\ the\\ expected\\ placement\\ of\\ the\\ right\\ kidney\\.\\ \\ \\ the\\ mass\\ appears\\ heterogeneous\\ with\\ multiple\\ cystic\\ components\\.\\ \\ the\\ mass\\ appears\\ somewhat\\ well\\ marginated\\.\\ \\ no\\ hypervascularity\\ is\\ seen\\.\\ \\ a\\ wedge\\ of\\ renal\\ parenchyma\\ can\\ be\\ seen\\ at\\ the\\ interface\\ of\\ the\\ tumor\\ and\\ the\\ liver\\ on\\ slide\\ \\#2\\.\ \(0\)\
\-\ abd\\.\\ ct\\:\\ \\ \\ a\\ 14cm\\,\\ heterogenous\\ renal\\ mass\\ extending\\ from\\ the\\ right\\ kidney\\ with\\ surrounding\\ rim\\ of\\ renal\\ parenchyma\\.\\ \\ there\\ are\\ multiple\\ low\\ density\\ collections\\ within\\ the\\ mass\\.\\ \\ there\\ is\\ no\\ evidence\\ of\\ fat\\ within\\ the\\ mass\\ or\\ calcifications\\ \\(suggesting\\ against\\ renal\\ angiomyolipoma\\ or\\ rhabdoid\\ tumor\\ of\\ the\\ kidney\\ respectively\\)\\.\\ \\ both\\ kidneys\\ demonstrate\\ contrast\\ enhancement\\ and\\ excretion\\.\\ \\ no\\ obvious\\ tumor\\ extensions\\ into\\ the\\ renal\\ vein\\ or\\ inferior\\ vena\\ cava\\ is\\ noted\\.\\ \\ mildly\\ enlarged\\ mesenteric\\ lymph\\ nodes\\ adjacent\\ to\\ the\\ kidney\\ suggest\\ possible\\ malignant\\ spread\\ or\\ may\\ be\\ reactive\\.\ \(0\)\
\-\ wilms\\â\\€\\™\\ tumor\\ \\(nephroblastoma\\)\\.\\ \\ negative\\ left\\ renal\\ involvement\\.\\ \\ negative\\ mesenteric\\ lymph\\ node\\ pathology\\.\ \(0\)\
\-\ renal\\ cell\\ carcinoma\ \(60\)\
\-\ wilms\\â\\€\\™\\ tumor\\ \\(nephroblastoma\\)\ \(0\)\
\-\ angiomyolipoma\ \(35\)\
\-\ soft\\-tissue\\ sarcoma\\ of\\ the\\ kidney\ \(0\)\
\-\ clear\\ cell\\ sarcoma\\ of\\ the\\ kidney\ \(0\)\
\-\ neuroblastoma\ \(81\)\
\-\ 13\\ year\\ old\\ caucasian\\ female\\ who\\ presented\\ to\\ the\\ er\\ following\\ a\\ two\\ week\\ history\\ of\\ right\\ sided\\ abdominal\\ pain\\ and\\ one\\ episode\\ of\\ hematuria\\ \\(patient\\ was\\ not\\ currently\\ menstruating\\)\\.\\ \\ patient\\ denies\\ fever\\,\\ weight\\ loss\\,\\ nausea\\,\\ vomiting\\.\ \(0\)\
\-\ wilms\\â\\€\\™\\ tumor\\ is\\ a\\ mixed\\ embryonal\\ neoplasm\\ that\\ is\\ the\\ most\\ common\\ intra\\-abdominal\\ tumor\\ and\\ renal\\ malignancy\\ in\\ childhood\\.\\ \\ it\\ is\\ the\\ fourth\\ most\\ common\\ pediatric\\ cancer1\\,2\\.\\ \\ \ \(0\)\
\-\ the\\ median\\ age\\ of\\ sporadic\\ wilms\\â\\€\\™\\ is\\ 44\\ months\\,\\ although\\ teenage\\ patients\\ \\(as\\ in\\ this\\ case\\ presentation\\)\\ may\\ present\\ with\\ it\\.\\ the\\ incidence\\ of\\ bilateral\\ tumours\\ is\\ between\\ 8\\â\\€\\“12\\%\\ and\\ the\\ gender\\ ratio\\ is\\ fairly\\ even\\ at\\ 1\\:1\\.2\\.\\ \\ the\\ mass\\ is\\ usually\\ smooth\\,\\ fixed\\ and\\ firm\\,\\ occasionally\\ extending\\ across\\ the\\ midline\\ of\\ the\\ abdomen\\.\\ \\ though\\ usually\\ asymptomatic\\,\\ 20\\-30\\%\\ of\\ patients\\ experience\\ hematuria\\,\\ abdominal\\ pain\\,\\ hypertension\\,\\ and\\ fever\\.\\ \\ symptoms\\ such\\ as\\ weight\\ loss\\,\\ cachexia\\,\\ or\\ bone\\ pain\\ are\\ uncommon\\ for\\ wilms\\â\\€\\™\\ tumor3\\.\ \(0\)\
\-\ wilms\\â\\€\\™\\ tumor\\ can\\ spread\\ locally\\ through\\ the\\ tumor\\ capsule\\ or\\ hematogenously\\ to\\ the\\ lungs\\,\\ liver\\,\\ or\\ the\\ other\\ kidney\\.\\ \\ it\\ may\\ progress\\ into\\ the\\ inferior\\ vena\\ cava\\ as\\ far\\ as\\ the\\ right\\ atrium3\\.\\ \ \(0\)\
\-\ wilms\\â\\€\\™\\ tumor\\,\\ which\\ is\\ intra\\-renal\\ in\\ development\\,\\ must\\ be\\ distinguished\\ from\\ neuroblastoma\\.\\ \\ neuroblastoma\\ typically\\ arises\\ in\\ the\\ adrenal\\ glands\\ and\\ is\\ the\\ second\\ most\\ common\\ childhood\\ solid\\ tumor\\.\\ \\ neuroblastomas\\ also\\ tend\\ to\\ have\\ calcifications\\,\\ another\\ difference\\ from\\ wilms\\â\\€\\™\\ tumors\\ that\\ may\\ be\\ discerned\\ radiologically1\\,\\ 4\\.\ \(0\)\
\-\ patients\\ with\\ chromosomal\\ aberrations\\ on\\ 11p13\\ and\\ 11p15\\ have\\ been\\ shown\\ to\\ be\\ at\\ increased\\ risk\\ of\\ wilms\\â\\€\\™\\ tumor\\.\\ \\ such\\ patients\\ may\\ present\\ with\\ other\\ conditions\\ that\\ include\\ aniridia\\,\\ mental\\ retardation\\,\\ macroglossia\\,\\ organomegaly\\,\\ or\\ genitourinary\\ anomalies3\\.\ \(0\)\
\-\ the\\ first\\ line\\ of\\ diagnostic\\ studies\\ for\\ wilms\\â\\€\\™\\ tumor\\ is\\ ultra\\ sound\\,\\ providing\\ a\\ non\\-invasive\\ means\\ of\\ evaluating\\ tumor\\ mass\\ in\\ the\\ abdomen\\.\\ it\\ can\\ be\\ helpful\\ in\\ ruling\\ out\\ an\\ extra\\-renal\\ mass\\ \\(neuroblastoma\\)\\ or\\ hydronephrosis5\\.\\ \\ ct\\ becomes\\ especially\\ useful\\ in\\ detection\\ of\\ bilateral\\ tumors\\ and\\ in\\ evaluation\\ of\\ other\\ abdominal\\ structures\\,\\ peritoneum\\,\\ and\\ lymph\\ nodes\\.\\ \\ on\\ ct\\ wilms\\â\\€\\™\\ tumor\\ appears\\ as\\ a\\ heterogenous\\,\\ enhancing\\ mass\\ with\\ less\\ than\\ 10\\%\\ showing\\ calcification\\.\\ \\ a\\ \\â\\€\\œclaw\\ sign\\"\\ of\\ the\\ displaced\\ renal\\ tissue\\ may\\ be\\ seen2\\.\\ \\ on\\ mri\\ the\\ tumors\\ are\\ hypointense\\ with\\ t1\\,\\ variable\\ with\\ t2\\,\\ and\\ enhance\\ poorly\\ with\\ gadolinium\\.\\ \\ gadolinium\\ is\\ given\\,\\ however\\,\\ to\\ evaluate\\ the\\ other\\ kidney\\ for\\ another\\ wilms\\â\\€\\™\\ mass2\\.\ \(0\)\
\-\ a\\ chest\\ xray\\ is\\ important\\ when\\ evaluating\\ a\\ patient\\ preoperatively\\ for\\ lung\\ metastasis\\.\\ \\ most\\ centers\\,\\ however\\,\\ prefer\\ the\\ use\\ of\\ chest\\ ct\\.\\ \\ though\\ chest\\ ct\\ is\\ a\\ sensitive\\ modality\\ for\\ wilms\\ tumor\\,\\ it\\ is\\ susceptible\\ to\\ false\\ positives\\ for\\ lung\\ metastasis\\ as\\ well\\ as\\ inter\\-reader\\ variability\\.\\ \\ histological\\ assessment\\ may\\ show\\ the\\ presence\\ of\\ nephrogenic\\ rests\\,\\ primordial\\ precursor\\ lesions\\ in\\ the\\ kidney\\,\\ common\\ in\\ the\\ setting\\ of\\ wilms\\â\\€\\™\\ tumor6\\.\ \(0\)\
\-\ nearly\\ all\\ patients\\ undergo\\ surgery\\ as\\ the\\ primary\\ treatment\\ method\\.\\ \\ chemotherapeutic\\ regimens\\ of\\ vincristine\\,\\ doxorubicin\\,\\ and\\ dactinomycin\\ with\\ or\\ without\\ radiation\\ therapy\\ \\(depending\\ on\\ the\\ stage\\ of\\ the\\ tumor\\)\\ are\\ used\\ in\\ treating\\ wilms\\â\\€\\™\\ tumor\\.\\ \\ \\ bilateral\\ renal\\ involvement\\ is\\ considered\\ stage\\ v\\ disease3\\.\ \(0\)\
\-\ relapse\\ rates\\ are\\ relatively\\ low\\ with\\ 10\\-15\\%\\ experiencing\\ relapse\\ in\\ patients\\ with\\ favorable\\ histologic\\ findings\\.\\ \\ they\\ increase\\ up\\ to\\ 50\\%\\ in\\ patients\\ with\\ anaplastic\\ findings3\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ wilms\\:\\ 0\\.47471068143608824\ \(0\)\
\-\ tumor\\:\\ 0\\.2715006583060777\ \(0\)\
\-\ the\\:\\ 0\\.25317625176978237\ \(0\)\
\-\ renal\\:\\ 0\\.21549060277540333\ \(0\)\
\-\ kidney\\:\\ 0\\.20258974873379976\ \(0\)\
\-\ of\\:\\ 0\\.15236783052040714\ \(0\)\
\-\ is\\:\\ 0\\.15004641981247926\ \(0\)\
\-\ mass\\:\\ 0\\.12116417068144963\ \(0\)\
\-\ patients\\:\\ 0\\.11355631909655389\ \(0\)\
\-\ in\\:\\ 0\\.10760525912912339\ \(0\)\
\-\ neuroblastoma\\:\\ 0\\.10597704111656862\ \(0\)\
\-\ may\\:\\ 0\\.10158144879919308\ \(0\)\
\-\ or\\:\\ 0\\.10031842767793067\ \(0\)\
\-\ as\\:\\ 0\\.09267843764700205\ \(0\)\
\-\ and\\:\\ 0\\.08938187380325902\ \(0\)\
\-\ be\\:\\ 0\\.08188583215837064\ \(0\)\
\-\ abdominal\\:\\ 0\\.07885831784313019\ \(0\)\
\-\ nephroblastoma\\:\\ 0\\.07702602263546608\ \(0\)\
\-\ relapse\\:\\ 0\\.07596077842934376\ \(0\)\
\-\ it\\:\\ 0\\.07380602102330708\ \(0\)\
\-\ with\\:\\ 0\\.07340612271914318\ \(0\)\
\-\ lymph\\:\\ 0\\.0672715632550858\ \(0\)\
\-\ right\\:\\ 0\\.06692437009117784\ \(0\)\
\-\ common\\:\\ 0\\.06541529299492366\ \(0\)\
\-\ to\\:\\ 0\\.06488250704276222\ \(0\)\
\-\ tumors\\:\\ 0\\.06362415837150036\ \(0\)\
\-\ appears\\:\\ 0\\.06335187631458805\ \(0\)\
\-\ angiomyolipoma\\:\\ 0\\.06169503865695793\ \(0\)\
\-\ most\\:\\ 0\\.06003037638272694\ \(0\)\
\-\ other\\:\\ 0\\.05990185304160141\ \(0\)\
\-\ childhood\\:\\ 0\\.058363849474269716\ \(0\)\
\-\ evaluating\\:\\ 0\\.0580151780671324\ \(0\)\
\-\ vena\\:\\ 0\\.055724877336967356\ \(0\)\
\-\ cava\\:\\ 0\\.05545524885694007\ \(0\)\
\-\ ct\\:\\ 0\\.05489238596790168\ \(0\)\
\-\ are\\:\\ 0\\.054711453398645124\ \(0\)\
\-\ heterogenous\\:\\ 0\\.0543237062571984\ \(0\)\
\-\ obvious\\:\\ 0\\.05363408887352426\ \(0\)\
\-\ for\\:\\ 0\\.05244145186228381\ \(0\)\
\-\ on\\:\\ 0\\.0522554260942929\ \(0\)\
\-\ spread\\:\\ 0\\.05180926678244456\ \(0\)\
\-\ pediatric\\:\\ 0\\.05162543501267477\ \(0\)\
\-\ hematuria\\:\\ 0\\.05100713512551017\ \(0\)\
\-\ though\\:\\ 0\\.05010601148781739\ \(0\)\
\-\ mesenteric\\:\\ 0\\.049797270894030306\ \(0\)\
\-\ nodes\\:\\ 0\\.048993850868977167\ \(0\)\
\-\ sarcoma\\:\\ 0\\.0483809075216985\ \(0\)\
\-\ gadolinium\\:\\ 0\\.048055784047876846\ \(0\)\
\-\ another\\:\\ 0\\.04719741087048774\ \(0\)\
\-\ normal\\:\\ 0\\.047095645720981946\ \(0\)\
\-\ relatively\\:\\ 0\\.04696497606379092\ \(0\)\
\-\ parenchyma\\:\\ 0\\.04685073226296232\ \(0\)\
\-\ bilateral\\:\\ 0\\.046494036663594404\ \(0\)\
\-\ tumor3\\:\\ 0\\.046116475112836744\ \(0\)\
\-\ atrium3\\:\\ 0\\.046116475112836744\ \(0\)\
\-\ discerned\\:\\ 0\\.046116475112836744\ \(0\)\
\-\ radiologically1\\:\\ 0\\.046116475112836744\ \(0\)\
\-\ aberrations\\:\\ 0\\.046116475112836744\ \(0\)\
\-\ 11p13\\:\\ 0\\.046116475112836744\ \(0\)\
\-\ 11p15\\:\\ 0\\.046116475112836744\ \(0\)\
\-\ anomalies3\\:\\ 0\\.046116475112836744\ \(0\)\
\-\ hydronephrosis5\\:\\ 0\\.046116475112836744\ \(0\)\
\-\ seen2\\:\\ 0\\.046116475112836744\ \(0\)\
\-\ mass2\\:\\ 0\\.046116475112836744\ \(0\)\
\-\ variability\\:\\ 0\\.046116475112836744\ \(0\)\
\-\ tumor6\\:\\ 0\\.046116475112836744\ \(0\)\
\-\ disease3\\:\\ 0\\.046116475112836744\ \(0\)\
\-\ findings3\\:\\ 0\\.046116475112836744\ \(0\)\
\-\ stage\\:\\ 0\\.04592849565743393\ \(0\)\
\-\ chest\\:\\ 0\\.045664725567479726\ \(0\)\
\-\ can\\:\\ 0\\.04539806897124218\ \(0\)\
\-\ cvat\\:\\ 0\\.04406675395069045\ \(0\)\
\-\ extensions\\:\\ 0\\.04406675395069045\ \(0\)\
\-\ neuroblastomas\\:\\ 0\\.04406675395069045\ \(0\)\
\-\ primordial\\:\\ 0\\.04406675395069045\ \(0\)\
\-\ 14cm\\:\\ 0\\.04261245364202563\ \(0\)\
\-\ aniridia\\:\\ 0\\.04261245364202563\ \(0\)\
\-\ dactinomycin\\:\\ 0\\.04261245364202563\ \(0\)\
\-\ course\\:\\ 0\\.04260094562489684\ \(0\)\
\-\ lungs\\:\\ 0\\.04256370628703921\ \(0\)\
\-\ metastasis\\:\\ 0\\.04227062869994508\ \(0\)\
\-\ calcifications\\:\\ 0\\.04209167767793998\ \(0\)\
\-\ involvement\\:\\ 0\\.041743006270802664\ \(0\)\
\-\ menstruating\\:\\ 0\\.041484410685482996\ \(0\)\
\-\ teenage\\:\\ 0\\.041484410685482996\ \(0\)\
\-\ hematogenously\\:\\ 0\\.041484410685482996\ \(0\)\
\-\ macroglossia\\:\\ 0\\.041484410685482996\ \(0\)\
\-\ ultra\\:\\ 0\\.041484410685482996\ \(0\)\
\-\ seen\\:\\ 0\\.04072853197870456\ \(0\)\
\-\ cachexia\\:\\ 0\\.040562732479879335\ \(0\)\
\-\ preoperatively\\:\\ 0\\.040562732479879335\ \(0\)\
\-\ prefer\\:\\ 0\\.040562732479879335\ \(0\)\
\-\ chemotherapeutic\\:\\ 0\\.040562732479879335\ \(0\)\
\-\ weight\\:\\ 0\\.04021880162883306\ \(0\)\
\-\ liver\\:\\ 0\\.039786047891415634\ \(0\)\
\-\ positives\\:\\ 0\\.039783464660570755\ \(0\)\
\-\ inferior\\:\\ 0\\.03923643058177482\ \(0\)\
\-\ precursor\\:\\ 0\\.03910843217121452\ \(0\)\
\-\ extending\\:\\ 0\\.03910357099849195\ \(0\)\
\-\ fever\\:\\ 0\\.03910357099849195\ \(0\)\
\-\ first\\:\\ 0\\.03892045271581171\ \(0\)\
\-\ hypervascularity\\:\\ 0\\.03851301131773304\ \(0\)\
\-\ ruling\\:\\ 0\\.03851301131773304\ \(0\)\
\-\ nephrogenic\\:\\ 0\\.03851301131773304\ \(0\)\
\-\ chemistry\\:\\ 0\\.03798038921467188\ \(0\)\
\-\ pod\\:\\ 0\\.03798038921467188\ \(0\)\
\-\ that\\:\\ 0\\.03754239479358153\ \(0\)\
\-\ patient\\:\\ 0\\.037516778982180865\ \(0\)\
\-\ no\\:\\ 0\\.037509722294760996\ \(0\)\
\-\ slide\\:\\ 0\\.03749857391513992\ \(0\)\
\-\ tumours\\:\\ 0\\.03749857391513992\ \(0\)\
\-\ regimens\\:\\ 0\\.03749857391513992\ \(0\)\
\-\ sided\\:\\ 0\\.037098722984076564\ \(0\)\
\-\ such\\:\\ 0\\.037098722984076564\ \(0\)\
\-\ claw\\:\\ 0\\.03705871100906822\ \(0\)\
\-\ chromosomal\\:\\ 0\\.03665407635983924\ \(0\)\
\-\ rests\\:\\ 0\\.03665407635983924\ \(0\)\
\-\ usually\\:\\ 0\\.03630778938543919\ \(0\)\
\-\ susceptible\\:\\ 0\\.03627944318975964\ \(0\)\
\-\ doxorubicin\\:\\ 0\\.03593066805252559\ \(0\)\
\-\ negative\\:\\ 0\\.03570545080799053\ \(0\)\
\-\ providing\\:\\ 0\\.03529793902676407\ \(0\)\
\-\ abdomen\\:\\ 0\\.03519062482252345\ \(0\)\
\-\ loss\\:\\ 0\\.03513698825748223\ \(0\)\
\-\ lung\\:\\ 0\\.03508363473631775\ \(0\)\
\-\ rbcs\\:\\ 0\\.03473566737009227\ \(0\)\
\-\ genitalia\\:\\ 0\\.03473566737009227\ \(0\)\
\-\ following\\:\\ 0\\.03459879334092006\ \(0\)\
\-\ locally\\:\\ 0\\.034476367743860765\ \(0\)\
\-\ from\\:\\ 0\\.03435837804714586\ \(0\)\
\-\ all\\:\\ 0\\.034331834761563595\ \(0\)\
\-\ however\\:\\ 0\\.03413614215951209\ \(0\)\
\-\ rhabdoid\\:\\ 0\\.03399455244432881\ \(0\)\
\-\ distinguished\\:\\ 0\\.03399455244432881\ \(0\)\
\-\ peritoneum\\:\\ 0\\.03399455244432881\ \(0\)\
\-\ vincristine\\:\\ 0\\.03399455244432881\ \(0\)\
\-\ embryonal\\:\\ 0\\.03376983836507976\ \(0\)\
\-\ gender\\:\\ 0\\.03376983836507976\ \(0\)\
\-\ retardation\\:\\ 0\\.03376983836507976\ \(0\)\
\-\ genitourinary\\:\\ 0\\.03376983836507976\ \(0\)\
\-\ centers\\:\\ 0\\.03376983836507976\ \(0\)\
\-\ 10\\:\\ 0\\.033724704812891595\ \(0\)\
\-\ difference\\:\\ 0\\.033554689538257104\ \(0\)\
\-\ sound\\:\\ 0\\.033554689538257104\ \(0\)\
\-\ gu\\:\\ 0\\.03315005488902813\ \(0\)\
\-\ low\\:\\ 0\\.03309353454739323\ \(0\)\
\-\ cell\\:\\ 0\\.032992066625372865\ \(0\)\
\-\ exploration\\:\\ 0\\.03295926868477564\ \(0\)\
\-\ favorable\\:\\ 0\\.03295926868477564\ \(0\)\
\-\ uneventful\\:\\ 0\\.032775421718948525\ \(0\)\
\-\ excretion\\:\\ 0\\.032775421718948525\ \(0\)\
\-\ sporadic\\:\\ 0\\.032775421718948525\ \(0\)\
\-\ at\\:\\ 0\\.03267618247808745\ \(0\)\
\-\ organomegaly\\:\\ 0\\.03242664658171447\ \(0\)\
\-\ means\\:\\ 0\\.032260886341439046\ \(0\)\
\-\ histologic\\:\\ 0\\.032260886341439046\ \(0\)\
\-\ radical\\:\\ 0\\.03194483128218251\ \(0\)\
\-\ xray\\:\\ 0\\.03194483128218251\ \(0\)\
\-\ histological\\:\\ 0\\.031793917555952955\ \(0\)\
\-\ method\\:\\ 0\\.031793917555952955\ \(0\)\
\-\ ctab\\:\\ 0\\.031647378762405885\ \(0\)\
\-\ treating\\:\\ 0\\.031647378762405885\ \(0\)\
\-\ anaplastic\\:\\ 0\\.031647378762405885\ \(0\)\
\-\ interface\\:\\ 0\\.03150496837611082\ \(0\)\
\-\ experiencing\\:\\ 0\\.03150496837611082\ \(0\)\
\-\ false\\:\\ 0\\.031100333726881833\ \(0\)\
\-\ pain\\:\\ 0\\.030956708274960994\ \(0\)\
\-\ oncology\\:\\ 0\\.030847519328478967\ \(0\)\
\-\ arises\\:\\ 0\\.030847519328478967\ \(0\)\
\-\ soft\\:\\ 0\\.030704299969436678\ \(0\)\
\-\ into\\:\\ 0\\.03065839537844188\ \(0\)\
\-\ glands\\:\\ 0\\.0306067483768661\ \(0\)\
\-\ noted\\:\\ 0\\.030578560466632584\ \(0\)\
\-\ marginated\\:\\ 0\\.030376925419568174\ \(0\)\
\-\ panel\\:\\ 0\\.03026581689426865\ \(0\)\
\-\ fairly\\:\\ 0\\.03026581689426865\ \(0\)\
\-\ tissue\\:\\ 0\\.03025437172592312\ \(0\)\
\-\ wedge\\:\\ 0\\.03015709798584136\ \(0\)\
\-\ detection\\:\\ 0\\.03005066806744599\ \(0\)\
\-\ rates\\:\\ 0\\.03005066806744599\ \(0\)\
\-\ service\\:\\ 0\\.029844303316507014\ \(0\)\
\-\ respectively\\:\\ 0\\.029844303316507014\ \(0\)\
\-\ median\\:\\ 0\\.029844303316507014\ \(0\)\
\-\ fixed\\:\\ 0\\.029744196393806658\ \(0\)\
\-\ present\\:\\ 0\\.029594296250614924\ \(0\)\
\-\ nephrectomy\\:\\ 0\\.02945524721396452\ \(0\)\
\-\ tend\\:\\ 0\\.02945524721396452\ \(0\)\
\-\ progress\\:\\ 0\\.029362488016975056\ \(0\)\
\-\ far\\:\\ 0\\.029362488016975056\ \(0\)\
\-\ ruq\\:\\ 0\\.029271400248137406\ \(0\)\
\-\ against\\:\\ 0\\.029181924737134858\ \(0\)\
\-\ ratio\\:\\ 0\\.028922625110903356\ \(0\)\
\-\ have\\:\\ 0\\.0288112229759463\ \(0\)\
\-\ nearly\\:\\ 0\\.028756864870627927\ \(0\)\
\-\ experience\\:\\ 0\\.02867597939465593\ \(0\)\
\-\ modality\\:\\ 0\\.028517990461674376\ \(0\)\
\-\ sensitive\\:\\ 0\\.02836478981642861\ \(0\)\
\-\ collections\\:\\ 0\\.028216095732122352\ \(0\)\
\-\ capsule\\:\\ 0\\.028216095732122352\ \(0\)\
\-\ assessment\\:\\ 0\\.028216095732122352\ \(0\)\
\-\ multiple\\:\\ 0\\.028209507246476893\ \(0\)\
\-\ across\\:\\ 0\\.028071650636844647\ \(0\)\
\-\ variable\\:\\ 0\\.0280009469052997\ \(0\)\
\-\ well\\:\\ 0\\.02792593475696731\ \(0\)\
\-\ female\\:\\ 0\\.02783026509106776\ \(0\)\
\-\ occasionally\\:\\ 0\\.02766154199206281\ \(0\)\
\-\ equal\\:\\ 0\\.02759631225607072\ \(0\)\
\-\ becomes\\:\\ 0\\.02759631225607072\ \(0\)\
\-\ ua\\:\\ 0\\.027531913494749538\ \(0\)\
\-\ useful\\:\\ 0\\.027531913494749538\ \(0\)\
\-\ depending\\:\\ 0\\.027468324802238535\ \(0\)\
\-\ pulses\\:\\ 0\\.02734349785766785\ \(0\)\
\-\ helpful\\:\\ 0\\.02734349785766785\ \(0\)\
\-\ undergo\\:\\ 0\\.026929387602292274\ \(0\)\
\-\ abd\\:\\ 0\\.02681704443676213\ \(0\)\
\-\ setting\\:\\ 0\\.02681704443676213\ \(0\)\
\-\ adrenal\\:\\ 0\\.026707143708481634\ \(0\)\
\-\ within\\:\\ 0\\.02656277048624985\ \(0\)\
\-\ episode\\:\\ 0\\.0263910886492251\ \(0\)\
\-\ conditions\\:\\ 0\\.0263402818456959\ \(0\)\
\-\ somewhat\\:\\ 0\\.026240174922995543\ \(0\)\
\-\ components\\:\\ 0\\.026190855171808025\ \(0\)\
\-\ firm\\:\\ 0\\.026142011947405897\ \(0\)\
\-\ uncommon\\:\\ 0\\.026093636129448476\ \(0\)\
\-\ poorly\\:\\ 0\\.026045718856949132\ \(0\)\
\-\ expected\\:\\ 0\\.025998251518533938\ \(0\)\
\-\ suggesting\\:\\ 0\\.025998251518533938\ \(0\)\
\-\ serum\\:\\ 0\\.02585846654616394\ \(0\)\
\-\ fourth\\:\\ 0\\.02585846654616394\ \(0\)\
\-\ enhance\\:\\ 0\\.025812717506337384\ \(0\)\
\-\ caucasian\\:\\ 0\\.0256337524669149\ \(0\)\
\-\ home\\:\\ 0\\.025503567562755083\ \(0\)\
\-\ 44\\:\\ 0\\.025503567562755083\ \(0\)\
\-\ hypointense\\:\\ 0\\.025376651246631982\ \(0\)\
\-\ mental\\:\\ 0\\.025131995388469337\ \(0\)\
\-\ showing\\:\\ 0\\.024898635447015153\ \(0\)\
\-\ kidneys\\:\\ 0\\.02482318278661077\ \(0\)\
\-\ incidence\\:\\ 0\\.02482318278661077\ \(0\)\
\-\ node\\:\\ 0\\.02478587461433072\ \(0\)\
\-\ discharged\\:\\ 0\\.024748839764448034\ \(0\)\
\-\ reactive\\:\\ 0\\.024748839764448034\ \(0\)\
\-\ must\\:\\ 0\\.024712074261311237\ \(0\)\
\-\ important\\:\\ 0\\.024427196957967225\ \(0\)\
\-\ even\\:\\ 0\\.024256970962631852\ \(0\)\
\-\ displaced\\:\\ 0\\.024092290785259606\ \(0\)\
\-\ cbc\\:\\ 0\\.024059988858107343\ \(0\)\
\-\ mixed\\:\\ 0\\.023870395348068032\ \(0\)\
\-\ development\\:\\ 0\\.023839476386856736\ \(0\)\
\-\ smooth\\:\\ 0\\.02380874538401765\ \(0\)\
\-\ suggest\\:\\ 0\\.02342536613148116\ \(0\)\
\-\ external\\:\\ 0\\.023313022965951016\ \(0\)\
\-\ mildly\\:\\ 0\\.02328532298212895\ \(0\)\
\-\ denies\\:\\ 0\\.023257773952646416\ \(0\)\
\-\ increase\\:\\ 0\\.023149055044219134\ \(0\)\
\-\ rim\\:\\ 0\\.022964247828716967\ \(0\)\
\-\ there\\:\\ 0\\.02294822314560742\ \(0\)\
\-\ especially\\:\\ 0\\.022811047183471198\ \(0\)\
\-\ pathology\\:\\ 0\\.02263799047659478\ \(0\)\
\-\ placement\\:\\ 0\\.022517908003887237\ \(0\)\
\-\ line\\:\\ 0\\.022470662478701234\ \(0\)\
\-\ considered\\:\\ 0\\.022470662478701234\ \(0\)\
\-\ evaluate\\:\\ 0\\.022423854418361935\ \(0\)\
\-\ shown\\:\\ 0\\.022354445075352825\ \(0\)\
\-\ currently\\:\\ 0\\.02215175819609234\ \(0\)\
\-\ nausea\\:\\ 0\\.02215175819609234\ \(0\)\
\-\ solid\\:\\ 0\\.022107799359105403\ \(0\)\
\-\ hypertension\\:\\ 0\\.022064219482323975\ \(0\)\
\-\ use\\:\\ 0\\.022064219482323975\ \(0\)\
\-\ diagnostic\\:\\ 0\\.02197817086179213\ \(0\)\
\-\ extremities\\:\\ 0\\.02191458216928113\ \(0\)\
\-\ 13\\:\\ 0\\.021748821929005697\ \(0\)\
\-\ midline\\:\\ 0\\.021688036815098413\ \(0\)\
\-\ structures\\:\\ 0\\.021667936453033703\ \(0\)\
\-\ malignancy\\:\\ 0\\.021588324817158944\ \(0\)\
\-\ second\\:\\ 0\\.021588324817158944\ \(0\)\
\-\ used\\:\\ 0\\.021588324817158944\ \(0\)\
\-\ er\\:\\ 0\\.02156861627601996\ \(0\)\
\-\ vomiting\\:\\ 0\\.021337919164405642\ \(0\)\
\-\ hospital\\:\\ 0\\.02130047281244842\ \(0\)\
\-\ studies\\:\\ 0\\.021153401075524225\ \(0\)\
\-\ clear\\:\\ 0\\.02090589261767575\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.020871503135401332\ \(0\)\
\-\ presence\\:\\ 0\\.020719581486847806\ \(0\)\
\-\ vein\\:\\ 0\\.02066993885159291\ \(0\)\
\-\ risk\\:\\ 0\\.02060449801024514\ \(0\)\
\-\ they\\:\\ 0\\.02060449801024514\ \(0\)\
\-\ calcification\\:\\ 0\\.02058826931444849\ \(0\)\
\-\ otherwise\\:\\ 0\\.020555967387296228\ \(0\)\
\-\ malignant\\:\\ 0\\.020555967387296228\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.020476104203420564\ \(0\)\
\-\ palpable\\:\\ 0\\.02025897487337998\ \(0\)\
\-\ typically\\:\\ 0\\.02024381673788747\ \(0\)\
\-\ quadrant\\:\\ 0\\.020198613148471364\ \(0\)\
\-\ 50\\:\\ 0\\.020138963672931103\ \(0\)\
\-\ sign\\:\\ 0\\.019964125460972457\ \(0\)\
\-\ underwent\\:\\ 0\\.019864861007134832\ \(0\)\
\-\ presentation\\:\\ 0\\.01985083815653667\ \(0\)\
\-\ given\\:\\ 0\\.01983685409672276\ \(0\)\
\-\ neoplasm\\:\\ 0\\.019685529659650945\ \(0\)\
\-\ left\\:\\ 0\\.019673788572067683\ \(0\)\
\-\ enlarged\\:\\ 0\\.019658496256195854\ \(0\)\
\-\ although\\:\\ 0\\.019631606648119884\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.019631606648119884\ \(0\)\
\-\ less\\:\\ 0\\.01961821529088741\ \(0\)\
\-\ possible\\:\\ 0\\.019538603655012646\ \(0\)\
\-\ week\\:\\ 0\\.01939582759658467\ \(0\)\
\-\ back\\:\\ 0\\.019232131981373312\ \(0\)\
\-\ surrounding\\:\\ 0\\.019232131981373312\ \(0\)\
\-\ density\\:\\ 0\\.019121831582428167\ \(0\)\
\-\ radiation\\:\\ 0\\.01910972323077321\ \(0\)\
\-\ out\\:\\ 0\\.0189548982978502\ \(0\)\
\-\ between\\:\\ 0\\.018736818050592196\ \(0\)\
\-\ adjacent\\:\\ 0\\.018692081171025124\ \(0\)\
\-\ show\\:\\ 0\\.01830632536851766\ \(0\)\
\-\ age\\:\\ 0\\.018104089024830676\ \(0\)\
\-\ enhancing\\:\\ 0\\.01806459480520884\ \(0\)\
\-\ t1\\:\\ 0\\.017967188431341645\ \(0\)\
\-\ fat\\:\\ 0\\.017938328784555247\ \(0\)\
\-\ ultrasound\\:\\ 0\\.017787132934576465\ \(0\)\
\-\ primary\\:\\ 0\\.017731580349171543\ \(0\)\
\-\ evaluation\\:\\ 0\\.017586357166405903\ \(0\)\
\-\ when\\:\\ 0\\.017419154016344997\ \(0\)\
\-\ cystic\\:\\ 0\\.017367481664590217\ \(0\)\
\-\ carcinoma\\:\\ 0\\.01724892802100962\ \(0\)\
\-\ through\\:\\ 0\\.017165917380781798\ \(0\)\
\-\ include\\:\\ 0\\.017157690797356687\ \(0\)\
\-\ two\\:\\ 0\\.017124917688087445\ \(0\)\
\-\ presented\\:\\ 0\\.016816044591953138\ \(0\)\
\-\ been\\:\\ 0\\.016800702442395416\ \(0\)\
\-\ months\\:\\ 0\\.016785406713936038\ \(0\)\
\-\ blood\\:\\ 0\\.016747368653360403\ \(0\)\
\-\ enhancement\\:\\ 0\\.01659801556313493\ \(0\)\
\-\ t2\\:\\ 0\\.01659066249362164\ \(0\)\
\-\ therapy\\:\\ 0\\.016568667240361924\ \(0\)\
\-\ lesions\\:\\ 0\\.016561356704888158\ \(0\)\
\-\ one\\:\\ 0\\.016510476849366566\ \(0\)\
\-\ evidence\\:\\ 0\\.01636786557553549\ \(0\)\
\-\ than\\:\\ 0\\.016346816685725556\ \(0\)\
\-\ who\\:\\ 0\\.016311928801229232\ \(0\)\
\-\ both\\:\\ 0\\.016080869807518387\ \(0\)\
\-\ symptoms\\:\\ 0\\.015777916178451114\ \(0\)\
\-\ bone\\:\\ 0\\.015734309449903165\ \(0\)\
\-\ increased\\:\\ 0\\.01559362234107462\ \(0\)\
\-\ surgery\\:\\ 0\\.015503935167861764\ \(0\)\
\-\ upper\\:\\ 0\\.015409990826241596\ \(0\)\
\-\ without\\:\\ 0\\.015210378652137422\ \(0\)\
\-\ demonstrate\\:\\ 0\\.014991503150321736\ \(0\)\
\-\ mri\\:\\ 0\\.014802303897706544\ \(0\)\
\-\ exam\\:\\ 0\\.014516508058202565\ \(0\)\
\-\ case\\:\\ 0\\.014487343163467626\ \(0\)\
\-\ large\\:\\ 0\\.01444871654268968\ \(0\)\
\-\ up\\:\\ 0\\.014264526022246298\ \(0\)\
\-\ findings\\:\\ 0\\.014232165014805849\ \(0\)\
\-\ contrast\\:\\ 0\\.014011259172898968\ \(0\)\
\-\ treatment\\:\\ 0\\.013736543877656\ \(0\)\
\-\ also\\:\\ 0\\.01356404960894493\ \(0\)\
\-\ which\\:\\ 0\\.013112423694941725\ \(0\)\
\-\ by\\:\\ 0\\.012245818665344644\ \(0\)\
\-\ not\\:\\ 0\\.011384120730672468\ \(0\)\
\-\ an\\:\\ 0\\.011027132375711193\ \(0\)\
\-\ history\\:\\ 0\\.011017363803784338\ \(0\)\
\-\ was\\:\\ 0\\.01004994388504094\ \(0\)\
\-\ this\\:\\ 0\\.009908876904121594\ \(0\)\
\-\ year\\:\\ 0\\.008886963712526104\ \(0\)\
\-\ old\\:\\ 0\\.008534561462857353\ \(0\)\
